Anacor Pharmaceuticals to Present at Upcoming Investor Conferences

  Anacor Pharmaceuticals to Present at Upcoming Investor Conferences

Wedbush Securities Life Sciences Conference 2013 Canaccord Genuity Global
Growth Conference 2013

Business Wire

PALO ALTO, Calif. -- August 8, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the
company’s Chief Executive Officer, will provide a company overview at the
following investor conferences:

  *Wedbush Lifesciences Management Access Conference on Tuesday, August 13,
    2013 at 3:40 p.m. ET in New York, New York
  *Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14,
    2013 at 4:30 p.m. ET in Boston, Massachusetts

The events will be webcast live and may be accessed under “Events and
Presentations” on the Investors page of Anacor’s website at www.anacor.com. A
replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, an antifungal for the treatment of
onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365, an antibiotic for the treatment of
infections caused by Gram-negative bacteria. We have also discovered three
other compounds that we have out-licensed for further development — two are
licensed to Eli Lilly and Company for the treatment of animal health
indications and the third compound, AN5568, also referred to as SCYX-7158, is
licensed to Drugs for Neglected Diseases initiative, or DNDi, for human
African trypanosomiasis (HAT, or sleeping sickness). We also have a pipeline
of other internally discovered topical and systemic boron-based compounds in
development. For more information, visit http://www.anacor.com.

Contact:

Anacor Pharmaceuticals
DeDe Sheel
Director, Investor Relations and Corporate Communications
650-543-7575